Magadh Chronicle

Cutaneous T-cell Lymphoma Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Pfizer, Eisai, Citius Pharmaceuticals

 Breaking News
  • No posts were found

Cutaneous T-cell Lymphoma Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Pfizer, Eisai, Citius Pharmaceuticals

November 14
23:57 2022
Cutaneous T-cell Lymphoma Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Pfizer, Eisai, Citius Pharmaceuticals
The emerging drugs shall significantly impact the cutaneous T-cell lymphoma (CTCL) market size, considering the robust pipeline with a large variety of therapeutic classes in the periphery. Presently, many biologics and drugs are under investigation for CTCL treatment. Key players such as Soligenix, Eisai, Merck Sharp & Dohme, Innate Pharma, 4SC AG, Beigene, and others will boost the cutaneous T-cell lymphoma market dynamics in the coming years.

DelveInsight’s Cutaneous T-cell Lymphoma (CTCL) Market Insights report includes a comprehensive understanding of current treatment practices, cutaneous T-cell lymphoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan].

 

Cutaneous T-cell Lymphoma Overview

Cutaneous T-cell lymphoma (CTCL) is a group of diseases characterized by an abnormal accumulation of malignant T-cells in the skin, which can lead to the formation of rashes, plaques, and tumors. Furthermore, CTCLs account for more than three out of every four skin lymphomas diagnosed, and they frequently manifest as eczema-like skin rashes and can affect multiple body parts. The exact cutaneous T-cell lymphoma causes are still not known.

 

Cutaneous T-cell lymphoma symptoms include skin patches and lumps, enlarged lymph nodes, hair loss, thickening of the skin on the palms of the hands and soles of the feet, and rash-like skin redness that is intensely itchy all over the body.

 

A thorough clinical evaluation, detection of specific CTCL symptoms and physical findings, a detailed patient history, and a variety of specialized tests are used for cutaneous T-cell lymphoma diagnosis. 

 

Key Takeaways from the Cutaneous T-cell Lymphoma Market Report

  • As per DelveInsight analysis, the cutaneous T-cell lymphoma market size in the 7MM was valued at approximately USD 399 million in 2021.
  • As per the estimates, the total cutaneous T-cell lymphoma incident population in the 7MM was around 7,485 in 2021. 
  • Leading cutaneous T-cell lymphoma companies such as Pfizer, Eisai, Citius Pharmaceuticals, Bristol Myers Squibb, Merck, Kyowa Kirin, Medivir, Seagen, Soligenix, 4SC AG, Galderma, Equillium, Innate Pharma, BeiGene, Codiak BioSciences, Astex Pharmaceuticals, and others are developing novel cutaneous T-cell lymphoma drugs that can be available in the cutaneous T-cell lymphoma market in the upcoming years.
  • The cutaneous T-cell lymphoma therapies in the pipeline include SGX301, Pembrolizumab, Resminostat, CD11301, EQ101, Tolinapant (ASTX660), exoIL-12, Lacutamab, Remetinostat, Resminostat, Tislelizumab (BGB-A317),  and others.
  • Compared to other indications, CTCL has a good prognosis, which prevents treatment-related toxicity. There are many established patient advocacy groups and international collaborations for this indication.

 

Discover which therapies are expected to grab major cutaneous T-cell lymphoma market share @ Cutaneous T-cell Lymphoma Market Report

 

Cutaneous T-cell Lymphoma Epidemiology Segmentation

  • As per our analysis, there were around 7,485 cutaneous T-cell lymphoma incident cases in the 7MM in 2021.
  • Among the EU5 countries, Germany had the highest incidence of CTCL in 2021.

 

The cutaneous T-cell lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Incident Population of  CTCL
  • Type-specific Cases of CTCL
  • Sub-type specific incidence of CTCL
  • Gender-specific cases of CTCL
  • Stage-specific cases of CTCL 
  • Treatment-eligible incident population in early-and advanced-stage

 

Cutaneous T-cell Lymphoma Treatment Market 

A patient’s CTCL treatment plan is determined by several factors, including the person’s overall health, age, and disease stage. The type and extent of skin lesions (patches, plaques, or tumors), the number of Sézary cells in the blood, and transformation to large cell type or folliculotropic cancer (involving the hair follicles) all influence cutaneous T-cell lymphoma treatment options.

Patients with early-stage mycosis fungoides or Sézary syndrome may respond well to skin-directed therapies alone. In contrast, patients with advanced disease may require a combination of topical and systemic therapies (affecting the entire body). ISTODAX (romidepsin), VALCHLOR (mechlorethamine), UVADEX (methoxsalen), TARGRETIN (bexarotene), ADCETRIS (brentuximab vedotin), POTELIGEO (mogamulizumab), and ZOLINZA (vorinostat) are some of the FDA-approved drugs.

 

To know more about cutaneous T-cell lymphoma treatment options, visit @ New Treatment for Cutaneous T-cell Lymphoma 

 

Cutaneous T-cell Lymphoma Pipeline Therapies and Key Companies

  • SGX301: Soligenix
  • Pembrolizumab: Merck
  • Resminostat: 4SC AG
  • CD11301: Galderma
  • EQ101: Equillium

 

Scope of the Cutaneous T-cell Lymphoma Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Cutaneous T-cell Lymphoma Companies: Pfizer, Eisai, Citius Pharmaceuticals, Bristol Myers Squibb, Merck, Kyowa Kirin, Medivir, Wellness Pharma, Seagen, Soligenix, 4SC AG, Galderma, Equillium, and others
  • Key Cutaneous T-cell Lymphoma Therapies: SGX301, Pembrolizumab, Resminostat, CD11301, EQ101, and others
  • Cutaneous T-cell Lymphoma Therapeutic Assessment: Cutaneous T-cell Lymphoma current marketed and emerging therapies
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Cutaneous T-cell Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Cutaneous T-cell Lymphoma Market Access and Reimbursement

 

Discover more about drugs for cutaneous T-cell lymphoma in development @ CTCL Clinical Trials

 

Table of Contents

1

Key Insights

2

Report Introduction

3

Executive Summary

4

Key Events

5

SWOT Analysis

6

Epidemiology and Market Methodology

7

CTCL Market Overview at a Glance

7.1

Market Share (%) Distribution by Therapies in 2021

7.2

Market Share (%) Distribution by Therapies in 2032

8

Disease Background and Overview

8.1

Introduction

8.2

Classification

8.3

Symptoms

8.4

Etiopathogenesis

8.5

Genomic Landscape of SS/MF

8.6

Biomarkers

8.7

Diagnosis

8.8

Staging and Assessment

9

Treatment and Management of CTCL

10

Treatment Guidelines

11

Epidemiology and Patient Population of CTCL in the 7MM

11.1

Key Findings

11.1.1

Assumptions and Rationale

11.1.1.1 

United States

11.1.2.1 

The EU5

11.1.3.3 

Japan

11.2

Total Incident Population of CTCL in the 7MM

11.3

The United States

11.3.1 

Total Incident Population of CTCL in the United States

11.3.2 

Type-specific Cases of CTCL in the United States

11.3.3 

Subtype-specific Cases of MF in the United States

11.3.4 

Gender-specific CTCL cases in the United States

11.3.5 

Stage-specific Cases of CTCL in the United States

11.3.6 

Treatment-eligible Incident Population in Early-and Advanced-stages in the United States

11.4

The EU5

11.4.1 

Total Incident Population of CTCL in the EU5

11.4.2 

Type-specific Cases of CTCL in the EU5

11.4.3 

Subtype-specific Cases of MF in the EU5

11.4.4 

Gender-specific CTCL Cases in the EU5

11.4.5 

Stage-specific Cases of CTCL in the EU5

11.4.6 

Treatment-eligible Incident Population in Early-and Advanced-stages in the EU5

11.5

Japan

11.5.1 

Total Incident Population of CTCL in Japan

11.5.2 

Type-specific Cases of CTCL in Japan

11.5.3 

Subtype-specific Cases of MF in Japan

11.5.4 

Gender-specific CTCL cases in Japan

11.5.5 

Stage-specific Cases of CTCL in Japan

11.5.6 

Treatment-eligible Incident Population in Early-and Advanced-stages in Japan

12

Patient Journey

13

Key Endpoints in CTCL

14

Marketed Drugs

14.1

Key Competitors

15

Emerging Drugs

15.1

Key Competitors

16

CTCL: 7MM Market Analysis

16.1

Key Findings

16.2

Market Outlook

16.3

Attribute Analysis

16.4

Key Market Forecast Assumptions

16.5

Total Market Size of CTCL in the 7MM

16.6

The United States Market Size

16.6.1 

Total Market Size of CTCL in the United States

16.6.2 

Market Size of Early-stage CTCL by Therapies in First Line in the United States

16.6.3 

Market Size of Early-stage CTCL by Therapies in Second Line in the United States

16.6.4 

Market Size of Advanced-stage CTCL by Therapies in First Line in the United States

16.6.5 

Market Size of Advanced-stage CTCL by Therapies in Second Line in the United States

16.7

The EU-5 Market Size

16.7.1 

Total Market size of CTCL in the EU5

16.7.2 

Market Size of Early-stage CTCL by Therapies in First Line in the EU5

16.7.3 

Market Size of Early-stage CTCL by Therapies in Second Line in the EU5

16.7.4 

Market Size of Advanced-stage CTCL by Therapies in First Line in the EU5

16.7.5 

Market Size of Advanced-stage CTCL by Therapies in Second Line in the EU5

16.8

Japan

16.8.1 

Total Market size of CTCL in Japan

16.8.2 

Market Size of Early-stage CTCL by Therapies in First Line in Japan

16.8.3 

Market Size of Early-stage CTCL by Therapies in Second Line in Japan

16.8.4 

Market Size of Advanced-stage CTCL by Therapies in First Line in Japan

16.8.5 

Market Size of Advanced-stage CTCL by Therapies in Second Line in Japan

17

Unmet Needs

18

Market Access and Reimbursement

18.1

US

18.2

Europe

18.3

Japan

19

Appendix

19.1

Bibliography

19.2

Report Methodology

20

DelveInsight Capabilities

21

Disclaimer

22

About DelveInsight

 

Learn more about the cutaneous T-cell lymphoma therapies in clinical trials @ Drugs for CTCL Treatment  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting